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Application of Cine Nuclear Magnetic Resonance Imaging for
Sequential Evaluation of Response to Angiotensin-Converting Enzyme
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GARY R . CAPUTO, MD . MARGARET O'SULLIVAN . RN, SAMUEL M . SOBOL . MD,
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Cine nuclear magnetic resonance (NMR) imaging was used to
serily measure cardiovascular function in 17 patients with New
York Head Assecintinn dust 11 or III heart rail- and left
ventricular ejection fruclinn w l$% who were treated fur 3 months
with benarepril hydrochloride, a new angialennie .cnnverttng en •
asme inhibitor, while continuing treatment with diuretic agents
and digositt, Interobserver reproducibilities for ejection fraction
(r = 0,94, SEE 3 .3%) . end-systolic volume (r = 0 .98, SEE
10
.5 call, end
•diahu9tic volume Ir = 0 .99, SEE 5
.29 ml), end.
systolic mass be = fear., SEF 15.2 g), end-syaotte wall
srraot (r =
0.91, SEE 10 dydes-s-cm
')
and end-systotie slresshrolurne ratio
(r = 0
.55, SEE 0 .13) demonstrated app9eahility of cine Nb1R
imaging for the serial assessment of cardiovascular function in
response to pharmacologic interventions in patients with heart
failure.
Recent studies (1) have shown that cine nuclear magnetic
resonance (NMR) imaging demonstrates close interstudy
reproducibility, which suggests that it would be an effective
technique for measuring small decreases in cardiac volumes
and ejection fraction that have been shown to accompany
cogietensin-converting enzyme inhibitor therapy in heart
failure (2)
.
Because cine NMR imaging is essentially a
three-dimensional imaging technique, it should be sensitive
for detecting any regression of eccentric hypertrophy in
heart failure that occurs with angiotensin-conversing enzyme
therapy . Cine NMR ©n also provide an estimate of Icfr ven-
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During 12 weeks of leatmeut with urnaaepril, ejection hoc-
Hon increased progressively from 2- .7 m 2.254 (mean s SEM) to
36 ± 2.2% (p < OAS). end-diaelolic vvlnme decreased from ICA on
14 to 159 s 12 m1 (p = NS), end •systolk volume decreased Iron
118 ± 12 m 106 ± 11 ml
(9 < 0
.05), tell venlricular mass
decreased from 235 x 13 to 220 a 12 g (p < 0 .05), end•sysiolk
wall stress decreased 29% from 90 { 5 to 64 * S dyness-em''
(p C 0,051, end 5ystolte pressure decreased from 92 .6 m 3,7 to
78.8 ± 5.3 (9 < 0.05) and and-systolic srress(vnlmne ratio, a
Mad .lndrpendent index of contractility, deertoaod from 0.0
0
0,05 to 0.67 d: 046 (p < 0.05), demonelrafing that improved
ejection fraction is doe to aRerlond reduction .
(J Am CoU Cordial 1992;19:1294-302)
iricolar end-systolic stresslvolume ratio, a load •indepemdent
index of contractility, which can be used tc detect any negative
inotropic effects due to the inhibition of angiatntsin B with
angiotensin•converting enzyme therapy (3) .
Therefore, to assess its feasibility to quantify the re-
sponse m therapy in dilated cardiomyopathy, cine NMR
imaging was used to serially measure left ventricular vol-
umes, ejection fraction, mass, wall stress and end-systolic
stresslvolume ratio in 17 patients with this condition . All had
New York Heart Association class 11 or 111 heart failure and
left ventricular ejection fraction r445% and
were treated over
a 3-month period with benazepeil hydrochloride (4,5), a new
angotensin-comeding enzyme inhibitor, while continuing
treatment with diuretic agents and digoxin in a single
.blind
study
.
Methods
Protocol. Patients with New York Heart Association
class II or Ill congestive heart failure, systolic blood pres-
sure >90 mm Hg and left ventricular ejection fraction
<0.45%a on echocardiography or radionuclide scan within 3
4715-1497107113,00
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'New York Heart Association classification . NMR = nuclear magnetic
resonance imaging.
months were considered for the protocol . Men and women
who were not of childbearing potential, as defined by being
either surgically sterilized or I year post-menopausal . were
eligible . All patients signed a
written
it:f4rined consent form
before entry into the study and were screened for safety
before undergoing NMR imaging. The study was approved
by the Human Research Review Committee at the Univer-
sity of California at San Francisco on August 29, 1989 .
Patients were seen for a screening visit at which they
were selected for entry into the study if they had a left
ventricular ejection fraction <0.45% on the screening two-
dimensional echocardiogram, along with a history, physical
examination, electrocardiogram (ECG), chest radiograph
and routine laboratory tests consistent with stable conges-
tive heart failure . Patient characteristics are described in
Table 1 . Table 2 lists the reason for withdrawal from the
study for seven patients. These seven patients are not
included among the 17 patients described in Table I and their
data are not analyzed in the results,
At the initial visit, all angiotensin-cunverting enzyme
inhibitors and other vasodilators, with the exception of
short-acting nitrates, were discontinued . Diuretic drugs and
digoxin were continued and doses maintained as constant as
possible throughout the study. Patients then entered a
2-week single-blind placebo ran-in period, at the end of
which the control tine NMR imaging was performed . Pa-
tients meeting all envy criteria listed were placed on treat-
Table 2 . Reasons for Withdrawal From the Trial (7 patients)
Hypelension 1
Perforated ulcer I
Fatigue I
Hypertension I
Digitalis toxicity (alrial bigeminy) I
Claustrophobia
	
2
DOttERTY Er AL .
CINE NMR IMAGING EVALUATION OF ACE INHIBITOR
1295
meet with benazepril (Lotensml, 5 mg once daily
. Dose
titration to 10 and 20 mg was made at 2 and 4 weeks .
respectively. after the start of active treatment if the pa-
tients' sitting systolic blood pressure was ?90 men Hg and
there was no evidence of toxicity (hypotension . for exam-
ple) . Patients underwent 12 weeks of therapy with this drug .
Cine NMR imaging was repeated at 4, 8 and 12 weeks of
therapy
.
Nuclear magnetic resonance imaging. Cane NMR images
were acquired along the short ixis of the heart (6) with echo
delay time (TE) 5 ms, repetit:en time (TR) 20 ms, and flip
angle 30° in 10-mm ce^tiesesi slices from apex to base with
no gaps between slices, using a 1
.5T Signa MRl scanner
(General Electric). No gap between slices vlas accomplished
by interdigitating slices on alternating acquisitions . Two
slices were acquired during each acquisition : 8 to 12 tomo-
graphic levels were acquired for each study to encompass
the entire left ventricle
.
Image analysis . Images were ant-Jyzed independently by
two observers off-line on an image analysis console provided
by the manufacturer of the NMR imagers. Standardized
width and level settings were used for image display to trace
epicardial and endocardial borders for each slice (7) . The
endocardial and epicardial borders were hand-drawn rte
standardized width and level settings . Left ventricular end-
systolic mass was calculated with Simpson's rule (8 .9) .
End-diastolic volume was calculated at 32 ms after the
R wave and end-systole as the smallest volume on each slice
occurring between 300 and 350 ms after the R wave . End-
diastolic and end-systolic areas for each anatomic slice were
summed from apex to base and their difference was deter-
mined to be the stroke volume (10).
Ejection fraction was
then calculated by dividing stroke volume by the end-
diastolic volume (11 .12). The analysis of the images for each
study required approximately 60 to 90 min .
Blood pressure a•Td
heart rare were taken immediately
after the NMR imaging. The values were the average of three
measure measure.cuts from an automated digital cuff (Dynamapp)
taken with the patient supine in an antechamber adjacent to
the imaging suite. Carotid pulse tracings were taken simul-
taneously to estimate left ventricular end-systolic pressure .
The dicrotic notch of the carotid pulse was used to define
end-systole. The ratio of the height of the dicrotic notch to
the peak amplitude of the pulse was multiplied by the
difference between the systolic and diastolic blood pressure
readings and this was added to the diastolic pressure to
derive the end-systolic pressure . This is expressed by for-
mula 1 :
LVESP-(DN a,,,p,IPSP5a,q)x(SBP-DBP)+DBP, [I]
where LVESP = left ventricular end systolic pressure,
DNampt
= dicrotic notch pressure amplitude on carotid pulse
tracing, PSPampt = peak systolic pressure amplitude on
carotid pulse tracing, SBP = peak systolic blood pressure
from blood pressure cuff and DBP= diastolic blood pressure
from blood pressure ouO
(1) .
Took 1
. Clinical Characteristics of 17 Patients Who Completed
the Study
Age (yr)
Range 34 to 11
Mean SD 55 = 1'-.5
Gender
Male 14
Female 3
Baseline ejection fraction I%t
Echocardiography
3120 II
Cane NMR 19
.7 _ -,
Heats failure fonctionat class`
Class 11
Class Ill
Etiology of heart failure
Isehemtc bean diacaac
5
Idiopathic
Alcoholic
x
3
Viral
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The mid-ventricular slice leas seiecied f,s iaeasurenient
of end-systolic wall thickness and left ventricular chamber
dimension . Mean left ventricular wall thickness (h) was
determined from the average of anterior, lateral, posterior
and septa) measurements . Mean left ventricular chamber
dimension (d) was determined from the average of anterior-
posterior and septal-lateral axes from endocardial edge to
the opposite endocardial edge . Left ventricular end-systolic
wall stress (LVESWS) was calculated from formula (2) as
described by previous investigations (1) .
1 .35 x LVESP x it
LVESWS =	
4h (I+hld)
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Statistics. Linear regression analysis was performed to
calculate correlations between measurements by two inde-
pendent observers, along with the SEE for each measure-
ment of left ventricular end-diastolic volume, end-systolic
volume, stroke volume, ejection fraction, left ventricular
mass and left ventricular end-systolic wall stress . Mean
values of the two observers were used for a one-factor
analysis of variance of repeated measures ; differences were
considered significant at a level of p < 0 .05 with the use of
the Donnett test for multiple comparisons against a single
control group .
Results
Clinical response to benazepril . Twelve of the 17 patients
reported symptomatic improvement during treatment with
benazepril ; 5 indicated no noticeable change . Arterial blood
pressure was significantly reduced with benazepril from a
control value of 123 *_ 5/72 t 3 mm Hg to 115
t
4/65 ± 2 at
4 weeks (p < 0.05), 116 ± 5/69 t 3 at 8 weeks (p = NS) and
113 ± 19/62 ± 13 mm Hg at 12 weeks (p < 0 .05) of treatment .
There were no significant changes in heart rate, which was
77 ± 3 beals/,nin at the control study and 71 ± 3 at 4 weeks,
72 ± 3 at 8 weeks and 76 ± 3 bcatslmin at 12 weeks.
Cine NMR measurements
. Figure lA shows end-diastolic
and end-systolic cine NMR images of contiguous mid-
ventricular slices before treatment . Figure IR shows cine
NMR images at the same levels after 12 weeks of treatment
with benazepril . Figure 2 summarizes data from cite NMR
measurements of left ventricular ejection fraction, end-
diastolic volume, end-systolic volume and end-systolic mass
during the study.
The baseline ejection fraction determined by cine NMR
imaging (29 .7 ± 2
.2%) was not significantly different from
the value derived from two-dimensional echocardiography
(31 .2 ± 1 .2%) . Ejection fraction increased progressively
during treatment with the drug (Table 3) to 33 .8 ± 2.5% at 4
weeks, 36
.3
t
2 .5% at 8 weeks and 36 ± 2
.2% at 12 weeks
(p < 0 .(5 at 4, 9 and 12 weeks compared with the control
value). The left ventricular end-diastolic volume decreased
from 166 ± 14 ml at the control study to 155 ± 13 at 4 weeks
(p < 0
.05), 160 ± 14 at 8 weeks (p = NS) and 158 ± 12 ml at
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12 weeks (p = NS). Left ventricular end-systolic volume
significantly (p < 0 .05) decreased from 118 t 12 ml at the
control study to 105 t 12 at 4 weeks, 106 ± 12 at 8 weeks and
106 ± 11 ml at 12 weeks .
There was a progressive decrease
in
left ventricular
mass
over time. Left ventricular end-systolic mass decreased from
a control value of 235 ± 13 g to 220 t 12 g at 12 weeks (p <
0.05) . Left ventricular end-diastolic mass decreased from
236 ± 12 g to 219 ± 12 g at 12 weeks (p < 0.05) . Comparison
of the mass measurements at end-systole and end-diastole
showed a high correlation with an SEE between the two of
1 .2 g (Fig. 3) .
There was a progressive decline in the left ventricular
end-systolic wall stress during treatment with the drug (Fig.
4) . Left ventricular end-systolic wall stress significantly
decreased from 90 ± 5 -s-cm
-'
at the control study to 74 ±
6 at ', weeks, 70 ± 5 at 8 weeks and 64 ± 5 dynes-s-em 5
at
12 weeks. Thus, there was a 29% decrease in left ventricular
end-systolic wall stress in response to long-term administra-
tion of this angiotensin-converting enzyme inhibitor .
The left ventricular end-systolic wall stress and the vari-
ables contributing to it are listed in Table 4 . The most
important variable contributing to the decrease in the end-
systolic wall stress is the proportional decrease in the
end-systolic pressure, from 92 .6 t 3.7 mm Hg at the control
study to 78.8 ± 5 .3 mm Hg at 12 weeks
.
Left ventricular end-systolic stresslvolume ratio, which is
a load-independent index of contractility, decreased from
0.83±0.05to075±0
.05at4weeks (p=NS),0
.74t0
.06
at 8 weeks (p = NS) and 0.67 ± 0
.06 at 12 weeks (p < 0 .05),
suggesting a possible decline in contractility during treat-
ment with benazepril despite the decrease in end-systolic
volume and increase in ejection fraction (Fig. 5) .
Reproducibility of cine NMR measurements . Cine NMR
left ventricular measurements (of ejection fraction, end-
systolic and end-diastolic volume, stroke volume, mass,
end-systolic wall stress and end-systolic stresslvolume ratio)
all had a high degree of interobserver reproducibility
. Table
5 summarizes the interobserver regression equations for
each of these variables .
Discussion
Cine NMR imaging of the effect of benazeprii
. This study
has demonstrated that cine NMR imaging can achieve highly
reproducible measurements of left ventricular function that
can be used to serially assess patients' responses to phar-
macologic therapy of heart failure . Benazepril increased
ejection fraction and decreased arterial pressure, end-
systolic wall stress, end-systolic and end-diastolic volume,
end-diastolic and end-systolic mass and end-systolic stress/
volume ratio with improvement in most patients' self-
assessment of clinical status . The results reported are the
mean values obtained by two independent observers, but
because the results had the same significance for each
observer, conclusions were not altered by this analysis .
JACC Voi
. 19, No
. 6
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Cine iiMR imaging, coupled with blood pressure deter-
mination and carotid pulse tracing, enabled noninvasive
determination of left ventricular end-systolic wall stress .
Left ventricular end-systolic wall stress was significantly
Flgure 1 . A, End-diastolic and end-systolic tine NMR
images of contiguous slices before treatment. B, End-
diastolic and end-systolic tine NMR images of the same
contiguous slices displayed in panel A after 12 weeks of
treatment with an angiotensin-converting enzyme inhib-
itor (benazepril). A decrease in cod-systolic volume is
evident, but there is no apparent decrease in end-
diastolic volume .
A
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reduced during benazepril treatment . This reduction was
attributable to the significant decrease in the left ventricular
end-systolic pressure since the other variables, wall thick-
ness and chamber dimensions, did not change significantly .
1298
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Figure 2. Mean Value ± SE for cine NMR imaging measurements of
left ventricular ejection fraction (EF) (A), end-systolic volume
(LVESV) (B), end-diastolic volume (LVEDV) (C) and end-systolic
mass (D) at control (C) and after 4, 8 and 12 weeks of treatment with
benazepril. *p < 0.05 compared with control value .
Afterload reduction with benazepril was also reflected by
significant decreases in both systolic and diastolic blood
pressures
.
Left ventricular mass. There was a progressive decrease
in left ventricular mass over time . Angiotensin-converting
enzyme inhibitors have been shown to decrease mass in
concentric left ventricular hypertrophy induced by arterial
hypertension (13-16) . The mechanism of mass reduction in
Table 3
. Changes in Left Ventricular Volumes and
Ejection Fraction
Control 4 Weeks 8 Weeks 12 Weeks
EF 1%) 29.7 z 2.2 33.8 ± 2.5' 36.3 i 2 .5' 36 0 2 .2'
EDV (m0 166 z 14 155 z 13' 160 ± 14 158 ± 12
ESV)m3 118±12 105±12' 106 *_12' 106
It .SV(ml) 48x5 50±4 54±4 52±4
HR (beatslmin) 76.5 ± 3 .4 71.2 m 2 .5 72 .1 ! 2 .5 75.6 x 3.4
'p < 0 .05 compared with control value ; Schefffi F test one-factor one-way
analysis of variance for repeated measures . A
I
I
values are mean values a SE.
EDV - end-diastolic volume ; EF = ejection fiction ; ESV =
end-systolic,
volume ;
HR = heart rate ; SV = stroke volume.
e
4 e
wukk
12
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hypertensive patients may be related to inhibition of local
tissue angiotensin (17) or reduction of plasma catechol-
amines (5,11,18), because it does not appear to be directly
related to reduction in blood pressure (13-16) . Regression of
hypertrophy in hypertensive patients has been associated
with improvement in diastolic performance without deterio-
ration of systolic function (15), and such changes could
be associated with symptomatic improvements in heart
failure
.
End-systolic volume. Both end-systolic and end-diastolic
volume decreased in patients with heart failure treated with
benazepril . The decrease in end-systolic volume was of
greater magnitude than the decrease in end-diastolic volume .
Thus, although there appears to have been both afterload
and preload reduction accompanying benazepril treatment of
heart failure, the mechanism for improved ejection fraction
resulted primarily from reduced end-systolic volume .
A reduction in end-systolic volume usually occurs with
either decreased afterload or enhanced contractility
. After-
load was shown to decrease by the diminution of arterial
pressure and resultant end-systolic wall stress . Left ventric-
ular end-systolic stress/volume ratio slightly decreased after
12 weeks of treatment with benazepril . The mechanism of
this decrease is not clear but the reduction indicates that
there was no increase in contractility . Hence, the reduced
end-systolic volume and increased ejection fraction were
due to decreased afterload with benazepril
.
IACC V01. 19, No . 6
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Figure 3. Comparison of hit ventricular end-systolic
and eed-diastolic mass measurements show
a high cor-
relation (R = 0.91,) with a siaudard error of rile
estimatc (SEE) (1
.2 g)_
End-systolic stress/volume ratio. One possible explana-
tion for the decrease in left ventricular ead-systolic stress!
volume ratio would be a decrease in contractility with
angiotensin-converting enzyme inhibitor therapy . A decline
in contractility with angiotensin-converting enzyme inhibi-
tion was previously noted during bilateral intracoronary
injection of enalaprilat in patients with dilated cardiomyop-
athy, and may be due to angiotensin-converting enzyme
inhibition of the inotropic effect of angiotensin 11 (3). A
decrease in plasma catecholamine with angiotensin-
converting enzyme inhibition also occurs with angiolensin-
converting enzyme inhibitor therapy and may cause a de-
crease in contractility (19). Progress in the cardiomyopathic
process itself could also account for a decline in contractil-
ity.
Although useful as an index of contractility, the left
ventricular end-systolic stress/volume ratio as measured in
this study represents only a single point . It is therefore
inadequate to judge a small change in contractility . because
the pressure-volume relations described by Suga and Sa-
gawa (20) use a line generated with multiple points . Gener-
ation of such a line in our study would have required at least
two pressure-volume points. This would be
best done by
increasing afterload with phenylephrine and then repeating
cine NMR imaging with blood pressure and carotid pulse
Figure 4. Left ventricular end-systolic wall stress (ESWS) declined
progressively, decreasing 29% from the control value during the 12
weeks of treatment with benezepdl. "p
< 0.05.
100
0
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r
. 22.4 .0-91.
n e 0.96
SEE a 1
.220
LM Veredculor Ere-srmoac wan
grams
measurements to determine left ventricular end-systolic wall
stress and left ventricular end-systolic stress/volume ratio
.
There are several alternative
explanations for the de-
crease in left ventricular end-systolic wall stress. The de-
crease ie left ventricular end-systolic stressivolume ratio
may be primarily due to the decrease in left ventricular
end-systolic wall stress without any change in contractility
or it may be related to a change in end-diastolic volume (2l) .
Decreases in preload with angiotensin-converting enzyme
inhibition (4,5,22-29) may change pressure-volume rela-
tions
. It has been shown that left ventricular end-systolic
stress/volume ratio increases with end-diastolic volume
(21).
Finally, decreased filling of right and left atria due to a
reduction in preload may decrease intrapericardial pressure
and shift the passive pressure-volume relation downward .
Prior studies with angioensin-converting enzyme inhibi-
tors have demonstrated clinical improvement (23,24,30-32),
prolonged exercise tolerance (23,30-32) and improved sur-
vival (33,34). Hemodynamic studies (4,5,22-29) have shown
decreases in arterial pressure, end-systolic wall stress, heart
rate, right atrial pressure and pulmonary capillary wedge
pressure, with increases in cardiac output. Radionuclide and
echocardiographic studies (2,19,26,27,30-32,35-38) have
shown decreased end-systolic volume, decreased or un-
changed ead-diastolic volume and increased ejection frac-
tion.
Co.nparisun of NMR imaging with other ima~g tech-
niques . In addition to cine NMR imaging, cardiac catheter-
ization (4,5,22-29), echocardiography (19,34-37), radionu-
elide ventriculography (22,23,26,27,30-32) and cine
computed tomography (39) can provide volumes and ejec-
tion fraction with which to quantitate response to therapy .
Hemodynamic studies are invasive, difficult to justify repeat-
ing multiple times in a single patient and short-term studies
have not been predictive of long-term responsiveness to
therapy in heart failure (27). Echocardiographic volume and
mass measurements are subject to operator-dependent er-
rrs, such as foreshorteningof the long axis, especially when
the area-iength method is used for calculations (35-30) . The
same limitations are operative for cine computed tamogra-
13011 DOHERTY ET AL
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Tshle 4. Left Ventricular End-Systolic Wall Stress and Related Variables
'p < 0 .05 compared with ccniml value ; Schene F test one .Cactor one-way, analysis of variance for repeated
measures . All values are mean values *_ SE . DBP = diastolic blood pressure ; ESP = end-systolic pressure ; LV =
left ventricular
: LVESWS = left vemricular end-systolic wall class; SOP = systniic Mood pressure .
phy and tine NMR imaging if area-length and other methods
based on geometric models are employed . Radionuclide
ventriculography may provide very accurate volumetric
information but it cannot be used to measure left ventricular
mass or end-systolic wall-stress (22,23,26,27,30-32)
. Cine
computed tomography (39) and tine NMR imaging (I) may
be more reproducible between studies in the same patient
because measurements can be based on measurements of a
three-dimensional data set that is provided by a complete
stack of short-axis images of the left ventricle .
Previous trials using echocardiography or nuclear ven-
triculography to assess the response to angiotensin-
converting enzyme inhibitors in patients with heart failure
have not reported reproducibility of the measurements
(2,22-32,35-38). Good interstudy reproducibility has been
shown for tine NMR imaging in both normal (10) and
morphologically abnormal left ventricles (I) .
Echocardiog-
raphy (40-42) and radionuclide ventriculography (18,43,44)
have good interstudy reproducibility, although less than that
reported for tine NMR imaging . However, no direct com-
parisons of the techniques have yet been published . The
good interstudy and interobserver reproducibilities of tine
NMR imaging are most likely due to the accuracy provided
by adjacent tomographic imaging of the entire heart, which
equates to three-dimensional data .
Because of the precision achieved by tomographic imag-
ing and noninvasiveness of NMR imaging, it is an attractive
Figure 5. Left ventricular end-systolic wall
stress/volume
ratio
yLVESSVR), a load-independent index of contractility, decreased
over the 12 weeks of treatment with benazepril. *p < 0.05 .
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technique for measuring small changes in volumes and mass
in response to treatment of heart failure. As a result, it may
be statistically more powerful than alternative techniques
and may not require as many patients to demonstrate statis-
tically significant differences . For example, the interob-
server variability for left ventricular end-systolic mass in the
present study was 4.B ± 0 .6% . This paraltvls interstudy
variability of left ventricular end-systolic mass measure-
ments in dilated cardiomyopathy of 5 .1 ± 2.8% and 3 .8 ±
3.1% in a previous study (1). This precision enabled tine
NMR imaging to determine that a 7% decrease in left
ventricular mass was significant with only 17 patients .
There are several other advantages to using tine NMR
imaging rather than echocardiography or radionuclide yen-
triculography for the serial assessment of cardiovascular
response to therapy in heart failure. Problems with attenua-
tion or operator technique do not occur with NMR imaging .
The technique is capable of providing a full assessment of
systolic left ventricular function, including the load-
independent end-systolic stresslvolume ratio . However, it is
subject to limitations, including problems with acquiring
suboptimal imaging in some circumstances because of arti-
facts caused by patient motion, excessive respiratory mo-
tion, inadequate gating due to irregular heart rates and small
QRS complexes . Moreover, cine NMR imaging is not uni-
versally accessible and remains relatively expensive . Finally,
the long data acquisition period for tine NMR studies encom-
passing the entire heart, approximately I h, requires consider-
able compliance by patients . Faster NMR techniques are now
reducing this time.
Table S . Cine NMR Imaging Interobserver Reproducibility
NMR = nuclear magnene resonance
: SN = stmke)ealume.
Control
4
Weeks 3
Weeks 12 Weeks
LVESWS )dynes-s •cm - ' I
90 ± 5 74 2 6' 69 t 5' 64 x 5"
LV wall thickness (mm) 14.5 2 0.4 14 .6 x 0 .4 14 .5 t 0.5 14 .6 t 0.6
LV dimensions Imm) 51 .9 ! 2.1 49.5'_ 2 .5 48 a 2.5 47.3 x 2 .7
SHPInt. Hg) 122.725 114 .5
	
4 .4- 116 .5 4.7 112 .8x4.7'
DOP elm Hg) 71 .7 2 .7 65 .5_2 .4' 57,6 2.9 62 .3x3 .3'
ESP rmmHer
92623 .7 83 .-17 81 .3[3.8' 78 .815 .3'
Left Ventricular
Variables Regression Equation R
SEE
Ejection fraction
y -
1 .14 + 0.0996x 0.94 3 .3%
End-systolic volume
y -
8 .71 + 0.86. 0.98 10.611
End-diastolic volume y = 7 .31 + 0.91. 0.99 8.311
Stroke volume y = 0.60 + 1 .01x 0.90 6.9
End-systolic mass y = -5.98 + 1.04x 0 .96 15.4
End-diaslolic mass y = 12.26 + 0.95x 0 .95 14.6
End-systolic wall stress y = 5.63 + 0.88x 0.91 l0
End-systolic S/V ratio y = 0.09 + 0,98x 0.85 0.13
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Conclusions. Benazepril was well tolerated in patients
with class 11 and III heart failure . The NMR imaging studies
demonstrated sustained decreases in ventricular end-systolic
and end-diastolic volume with increased ejection fraction,
decreased left ventricular mass, decreased end-systolic wall
stress and decreased left ventricular end-systolic stress!
volume ratio after 12 weeks of treatment with benazepril .
This study demonstrated the cppli.ebih0y of dine NMR
imaging to noninvasive serial assessments of cardiovascular
function in response to phartnacologic interventions in pa-
tients with heart failure .
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